The Committee's recommendation was based on data from the omadacycline global development program that included nearly 2000 adults in three Phase 3 studies.
To investigate what impact antibiotic treatment duration has on CAP outcomes, researchers from the Warren Alpert Medical School of Brown University conducted a search of various databases for studies comparing the safety and efficacy of treatment regimens lasting ≤6 days (short) and ≥7 days (long).
PCV13, marketed as Prevnar 13, was evaluated in a test-negative case-control study in real-world conditions where patients were administered pneumococcal vaccination as advised by their healthcare providers.
In the LEAP 2 study (N=738), patients with moderate CABP received either oral lefamulin 600mg every 12 hours for 5 days or oral moxifloxacin 400mg once daily for 7 days
Omadacycline is an investigational, once-daily, broad-spectrum aminomethylcycline antibiotic that is related to tetracyclines.
The analysis found that 3% of Legionnaires' disease cases are definitely associated with a health care facility while 17% were deemed as possibly associated with a health care facility.
The researchers found that the total treatment failure rate was 22.1%, defined as either the need to refill antibiotic prescriptions, antibiotic switch, ER visit or hospitalization within 30 days of receiving initial antibiotic prescription.
More than half (54%) of a series of drug-related unexplained deaths in Minnesota between 2006 and 2015 listed pneumonia as the cause of death.
The favorable in vivo results further confirm the ongoing use of Vibativ for its use in HABP/VABP due to S. aureus, including MRSA.
Results showed that compared with current use of metformin + sulfonylurea, the use of thiazolidinediones + metformin was associated with an increased risk of CAP.
Analysis found that the use of benzodiazepines was significantly associated with an increased risk of pneumonia (aHR 1.28, 95% CI: 1.07-1.54) but not for the similarly acting non-benzodiazepines (aHR 1.10, 95% CI: 0.84-1.44).
The study met the primary and secondary endpoints, showing that omadacycline is non-inferior to moxifloxacin for the treatment of CABP.
For children with community-acquired pneumonia (CAP), patient and nonclinical characteristics are associated with receipt of macrolides and broad-spectrum antibiotics versus amoxicillin, according to a new study.
A Cochrane review found that polyvalent pneumococcal vaccines offered significant protection against community-acquired pneumonia (CAP) in chronic obstructive pulmonary disease (COPD) patients, however, the evidence did not show that vaccination lowered the risk of confirmed pneumococcal pneumonia.
Of the medical conditions tracked by the government to measure quality of care and guide pay-per-performance reimbursements, sepsis accounted for significantly more hospital readmissions and associated costs than any of the tracked conditions.
Findings from a U.S. claims-based retrospective study published in Hospital Practice call for the development of more effective antimicrobial treatments that have a reduced adverse events burden for patients with community-acquired pneumonia (CAP).
Researchers aimed to compare the risk of pneumonia with the use of donepezil, oral rivastigmine, transdermal rivastigmine, galantamine, and memantine.
For children with complicated pneumonia, peripherally inserted central venous catheter (PICC) and oral antibiotic administration post-discharge have similar rates of treatment failure.
The Food and Drug Administration (FDA)'s Antimicrobial Drugs Advisory Committee (AMDAC) voted 7-6 that the benefits of solithromycin outweigh the risks associated with this treatment for community-acquired bacterial pneumonia (CABP).